Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Cephalon
NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
NCT05467683 · Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, and more
NCT06846320 · Generalized Anxiety Disorder (GAD)
Birmingham Research Group
Birmingham, Alabama
Southwestern Research Institute
Beverly Hills, California
Pharmacology Research Institute
Northridge, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions